FDA green light for US Part 2 enrollment is a positive catalyst that reduces trial risk; monitor for IND amendment submission and initiation of US sites. TLX591-Tx's differentiated safety profile could support a competitive advantage in the prostate cancer therapy landscape.
Price Chart
Executive Summary
Telix announced FDA alignment to proceed to Part 2 of the ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, following successful review of safety data from Part 1. The FDA agreed on the clinical protocol and statistical plan, allowing US enrollment to begin upon IND amendment submission. This regulatory milestone de-risks the pivotal trial and supports TLX591-Tx's differentiated profile with no observed kidney toxicity.
Key Facts
- FDA confirmed Part 1 safety data sufficient to start Part 2 of ProstACT Global trial in the US.
- TLX591-Tx (177Lu rosopatamab tetraxetan) targets PSMA in metastatic castration-resistant prostate cancer.
- Two-dose regimen administered 14 days apart, combined with abiraterone, enzalutamide, or docetaxel.
- TLX591-Tx shows no significant kidney toxicity and minimal salivary/lacrimal uptake vs. other PSMA-targeted radioligand therapies.
- Part 2 enrollment already underway in multiple countries (Australia, NZ, Canada, Turkey, UK, China, Singapore, South Korea).
Financial Impact
FDA alignment on Phase 3 protocol reduces regulatory risk and supports pipeline value; TLX market cap ~$3.9B
Risk Factors
- IND amendment still pending FDA review before US enrollment can begin.
- Competition from existing PSMA-targeted radioligand therapies (e.g., Pluvicto).
- Enrollment delays or unexpected safety signals in Part 2 could impact timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3321065 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access